Novembrino Cristina, Quaglia Ilaria, Molinari Angelo Claudio, Borchiellini Alessandra, Coppola Antonio, Santoro Rita Carlotta, Boscolo-Anzoletti Massimo, Galbiati Eleonora, Zanon Ezio, Valpreda Alessandra
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20122 Milan, Italy.
Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital Rozzano, 20089 Milan, Italy.
Diagnostics (Basel). 2022 Aug 18;12(8):1999. doi: 10.3390/diagnostics12081999.
Recombinant porcine factor VIII (rpFVIII) is indicated for treating bleeding episodes in acquired haemophilia A, but there are few data regarding laboratory methods to adequately monitor treatment. This study involving three Italian laboratories aimed to evaluate the analytical performance of different assays for measuring rpFVIII. Five spiked rpFVIII samples (0.5-1.5 IU/mL) were analysed on three days, in triplicate, with eleven combinations of reagents (Werfen, Boston, MA, USA: SynthasIL and SynthaFax for one-stage assay, Chromogenix Coamatic FVIII for chromogenic assay), FVIII depleted plasmas (with or without von Willebrand factor-VWF) and calibrators (HemosIL human calibrator plasma, porcine calibrator diluted in FVIII deficient plasma with or without VWF). The assays were performed on ACL TOP analysers (Werfen, Boston, MA, USA). Intra- and inter-assay and inter-laboratory Coefficient of Variation (CV%) were calculated together with percentage of recovery (% recovery) on the expected value. The results showed that the reagent combinations reaching satisfactory analytical performance are: SynthasIL/human calibrator/deficient plasma+VWF (total recovery 99.4%, inter-laboratory CV 4.04%), SynthasIL/porcine calibrator/deficient plasma+VWF (total recovery 111%, inter-laboratory CV 2.75%) and Chromogenic/ porcine calibrator/deficient plasma+VWF (total recovery 96.6%, inter-laboratory CV 8.32%). This study highlights that the use of porcine standard (when available) and FVIII deficient plasma with VWF should be recommended.
重组猪因子VIII(rpFVIII)适用于治疗获得性血友病A的出血发作,但关于充分监测治疗的实验室方法的数据很少。这项涉及三个意大利实验室的研究旨在评估不同检测方法测量rpFVIII的分析性能。在三天内对五个加标的rpFVIII样本(0.5 - 1.5 IU/mL)进行分析,一式三份,使用十一种试剂组合(美国马萨诸塞州波士顿的Werfen公司:用于一期检测的SynthasIL和SynthaFax,用于发色检测的Chromogenix Coamatic FVIII)、VIII因子缺乏的血浆(有或没有血管性血友病因子 - VWF)和校准品(HemosIL人校准血浆、在有或没有VWF的VIII因子缺乏血浆中稀释的猪校准品)。检测在ACL TOP分析仪(美国马萨诸塞州波士顿的Werfen公司)上进行。计算批内和批间以及实验室间的变异系数(CV%)以及相对于预期值回收率(%回收率)。结果表明,达到令人满意分析性能的试剂组合为:SynthasIL/人校准品/缺乏血浆 + VWF(总回收率99.4%,实验室间CV 4.04%)、SynthasIL/猪校准品/缺乏血浆 + VWF(总回收率111%,实验室间CV 2.75%)和发色法/猪校准品/缺乏血浆 + VWF(总回收率96.6%,实验室间CV 8.32%)。这项研究强调应推荐使用猪标准品(如有)和含有VWF的VIII因子缺乏血浆。